Spots Global Cancer Trial Database for fludarabine
Every month we try and update this database with for fludarabine cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia | NCT00487448 | Myelodysplastic... Acute Myeloblas... | Fludarabine Cytarabine G-CSF Idarubicin Peripheral bloo... Bone marrow tra... | - 75 Years | PETHEMA Foundation | |
| Allogeneic γ9δ2 T Cells Treatment of Recurrent Hematologic Tumors | NCT05755854 | Hematologic Dis... | allogeneic γ9δ2... Fludarabine Cyclophosphamid... Zoredronic acid | 12 Years - 65 Years | Anhui Provincial Hospital | |
| Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma | NCT02280525 | Leukemia | Lenalidomide Rituximab Fludarabine Cyclophosphamid... NK Cells Cytarabine | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
| ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR) | NCT06415487 | Locally Advance... Metastatic Soli... | Cyclophosphamid... Fludarabine ACE2016 Pembrolizumab | 18 Years - | Acepodia Biotech, Inc. | |
| Comparative Study of BFC and BuCy Conditioning Regimen for Allo-PBSCT in Acute B-cell ALL | NCT05379569 | Acute B Lymphob... Allogeneic Hema... | Fludarabine | 18 Years - 55 Years | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | |
| TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer | NCT03287674 | Metastatic Ovar... | Cyclophosphamid... Fludarabine TIL infusion Interleukin-2 Ipilimumab Nivolumab | 18 Years - 70 Years | Herlev Hospital | |
| Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies | NCT00795132 | Acute Leukaemia Chronic Disease Leukemia Myelodysplasia Lymphoma | Busulfan Anti-Thymocyte ... Fludarabine Cyclosporine Mycophenolate m... | - 21 Years | University of Utah | |
| Optimizing PTCy Dose and Timing | NCT03983850 | Graft Versus Ho... Hematologic Neo... | Busulfan Fludarabine Cyclophosphamid... Mycophenolate M... Sirolimus | 12 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma | NCT02062359 | Metastatic Canc... Metastatic Mela... | Anti-NY ESO-1 T... Aldesleukin Cyclophosphamid... Fludarabine | 18 Years - 70 Years | National Institutes of Health Clinical Center (CC) | |
| Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies | NCT01203722 | Hematologic Mal... | Fludarabine Cytoxan Total Body Irra... Allogeneic Bloo... Peripheral Bloo... Mycophenolate M... Sirolimus Tacrolimus | 6 Months - 75 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation | NCT01810588 | Hematologic Mal... | CliniMACS® CD34... Fludarabine Melphalan anti-thymocyte ... Rituximab Total Body Irra... Mycophenolate M... Tacrolimus | 18 Years - | Weill Medical College of Cornell University | |
| Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma | NCT01814046 | Metastatic Ocul... Metastatic Uvea... | Aldesleukin Cyclophosphamid... Fludarabine Young Tumor Inf... | 16 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia | NCT04789408 | Acute Myeloid L... | Cyclophosphamid... Fludarabine KITE-222 | 18 Years - | Gilead Sciences | |
| A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT | NCT04217278 | Acute Myeloid L... High-risk Myelo... | Vyxeos Fludarabine Busulphan Thiotepa Cytarabine | 18 Years - | University of Birmingham | |
| Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia | NCT04881240 | Acute Lymphobla... Acute Lymphobla... Pediatric ALL | CD19-CAR(Mem) T... Cyclophosphamid... Fludarabine Mesna CliniMACS Leukapheresis | - 21 Years | St. Jude Children's Research Hospital | |
| Natural Killer Cell (CYNK-001) Infusions in Adults With AML | NCT04310592 | Leukemia Leukemia, Myelo... Leukemia, Myelo... Neoplasms by Hi... Neoplasms Immunosuppressi... Immunologic Fac... Physiological E... Alkylating Agen... Antimetabolites... Antiviral Agent... Analgesics, Non... Anti-infective ... Analgesics Peripheral Nerv... Hematologic Dis... Hematologic Neo... Leukemia in Rem... Relapsed Adult ... Refractory AML | CYNK-001 | 18 Years - 80 Years | Celularity Incorporated | |
| Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome | NCT00047060 | Mycosis Fungoid... Sezary Syndrome | A matched perip... cyclosporine fludarabine Campath | 18 Years - 70 Years | National Institutes of Health Clinical Center (CC) | |
| Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Secondary Myelofibrosis | NCT03118492 | Secondary Myelo... | Allogeneic Hema... Cyclophosphamid... Fludarabine Glycosylated Re... Laboratory Biom... Melphalan Mycophenolate M... Tacrolimus Total-Body Irra... | 18 Years - 65 Years | City of Hope Medical Center | |
| Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma | NCT03168438 | Neoplasms | Letetresgene au... Letetresgene au... Fludarabine Cyclophosphamid... Pembrolizumab | 18 Years - | GlaxoSmithKline | |
| Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT00193466 | Non-Hodgkins Ly... | Rituximab Fludarabine CAMPTH-1H | 18 Years - | SCRI Development Innovations, LLC | |
| Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplant (HSCT) For Lymphoma | NCT02724904 | Lymphoma | Allogeneic stem... Fludarabine Thiotepa Methotrexate | 18 Years - | Massachusetts General Hospital | |
| Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma | NCT00117156 | Lymphoma, Non-H... MALT Lymphoma | Fludarabine Rituximab | 18 Years - | Dana-Farber Cancer Institute | |
| Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor | NCT01598025 | Acute Leukemia Chronic Leukemi... Myelodysplastic... Non-Hodgkins Ly... | total-body irra... thiotepa fludarabine pho... melphalan anti-thymocyte ... allogeneic hema... peripheral bloo... laboratory biom... | - 19 Years | Memorial Sloan Kettering Cancer Center | |
| MINIALO-VELCADE2005: A Study of Bortezomib (Velcade) Treated Multiple Myeloma Patients Pre and Post Allogeneic Haematopoietic Progenitor Cell Transplant With no Myeloablative Conditioning | NCT00564200 | Multiple Myelom... | Bortezomib dexamethasone Fludarabine Melphalan | 18 Years - 66 Years | PETHEMA Foundation | |
| FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia | NCT00769522 | Chronic Lymphoc... | Rituximab Bendamustine Cyclophosphamid... Fludarabine | 18 Years - | German CLL Study Group | |
| Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL | NCT03602157 | Lymphoma Immune System D... Immunoprolifera... Lymphatic Disea... Lymphoprolifera... Neoplasms Cutaneous Lymph... Cutaneous Anapl... Mycosis Fungoid... Sezary Syndrome Lymphomatoid Pa... Cutaneous T Cel... Gray Zone Lymph... | ATLCAR.CD30.CCR... ALTCAR.CD30 cel... Bendamustine Fludarabine | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Nivolumab With Chemotherapy in Refractory MDS | NCT03259516 | Myelodysplastic... | Nivolumab Azacitidine Fludarabine Cyclophosphamid... Cytarabine all trans retin... Sildenafil Melphalan | 18 Years - 80 Years | St. Petersburg State Pavlov Medical University | |
| NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma | NCT05359211 | Recurrent Diffu... Recurrent Diffu... Recurrent Grade... Recurrent Prima... Refractory Diff... Refractory Diff... Refractory Grad... Refractory Prim... Transformed Ind... | Cyclophosphamid... Fludarabine Lisocabtagene M... Polymer-conjuga... X-Ray Imaging Echocardiograph... Multigated Acqu... Bone Marrow Bio... Bone Marrow Asp... Lumbar Puncture Computed Tomogr... Positron Emissi... Biospecimen Col... Biopsy | 18 Years - | Fred Hutchinson Cancer Center | |
| Rituximab, Fludarabine, and Cyclophosphamide or Observation Alone in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia | NCT00275054 | Chronic Lymphoc... | Fludarabine Cyclophosphamid... Rituximab | 18 Years - | German CLL Study Group | |
| Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A | NCT02406092 | Non-Hodgkin Lym... | Rituximab Cyclophosphamid... Doxorubicin Vincristine Prednisone Fludarabine | 18 Years - 80 Years | Hoffmann-La Roche | |
| Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome | NCT02212561 | Acute Myeloid L... Acute Lymphobla... Myelodysplastic... Mixed Phenotype... | Selinexor Fludarabine Cytarabine methotrexate/hy... | - 24 Years | St. Jude Children's Research Hospital | |
| Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS | NCT04893915 | Relapsed Acute ... Refractory Acut... Myelodysplastic... | Cytokine-induce... Fludarabine Cyclophosphamid... Donor Leukapher... Interleukin-2 | 18 Years - | Washington University School of Medicine | |
| Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201 | NCT06341647 | Breast Cancer Gastric Cancer Gastroesophagea... | AB-201 Cyclophosphamid... Fludarabine | 18 Years - | GC Cell Corporation | |
| Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders | NCT00636909 | AML ALL CML Chronic Pha... CLL MDS RELAPSED NON-HO... APLASTIC ANEMIA MULTIPLE MYELOM... MYELOPROLIFERAT... | Cyclophosphamid... fludarabine cyclosporine methotrexate G-CSF | - 65 Years | Beth Israel Deaconess Medical Center | |
| Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia | NCT04898894 | Acute Leukemia ... Acute Myeloid L... Refractory Acut... Refractory Acut... | Venetoclax Selinexor Cytarabine Fludarabine Filgrastim Methotrexate methotrexate/hy... | 2 Years - 30 Years | St. Jude Children's Research Hospital | |
| Infusion of Allogeneic, 3rd Party CD19-specific T Cells | NCT02274506 | Blood And Marro... Leukemia Lymphoma | Cyclophosphamid... Fludarabine T-Cell Infusion | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy | NCT00303719 | Kidney Cancer Leukemia Lymphoma Multiple Myelom... Plasma Cell Neo... Myelodysplastic... | anti-thymocyte ... cyclophosphamid... cyclosporine fludarabine mycophenolate m... stem cell trans... total body irra... filgrastim | - 75 Years | Masonic Cancer Center, University of Minnesota | |
| Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma | NCT04706936 | Relapsed or Ref... | anti-BCMA CAR-T Cyclophosphamid Fludarabine | 18 Years - 75 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| CAR-T Cells in Treating Patients With Relapsed or Refractory NHL | NCT04626739 | Refractory Indo... | CD19 CAR-T CD22 CAR-T CD19+CD22 CAR-T Fludarabine Cyclophosphamid... | 18 Years - 75 Years | Hebei Senlang Biotechnology Inc., Ltd. | |
| Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation | NCT04395222 | Hematologic Mal... Bone Marrow Tra... | Tocilizumab Fludarabine Melphalan Anti-thymocyte ... Total Body Irra... | 18 Years - | Weill Medical College of Cornell University | |
| Conditioning Treatment With Umbilical Cord Blood Transplant for Hematologic Malignancies | NCT01622556 | Hematologic Mal... | Fludarabine Busulfan Thymoglobulin Total Body Irra... Umbilical Cord ... | 18 Years - 70 Years | University of Virginia | |
| T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers | NCT02280811 | Vaginal Cancer Cervical Cancer Anal Cancer Penile Cancer Oropharyngeal C... | Fludarabine Cyclophosphamid... E6 TCR Aldesleukin | 18 Years - 70 Years | National Institutes of Health Clinical Center (CC) | |
| Reduced Intensity Conditioning (RIC) Regimen and Post-transplant Cyclophosphamide in Haploidentical Bone Marrow Transplantation in in Patients With Poor Prognosis Lymphomas | NCT02049580 | Lymphoma | Thiotepa Fludarabine Cyclophosphamid... | 18 Years - 70 Years | Istituto Clinico Humanitas | |
| Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia | NCT03860844 | Acute Lymphobla... Acute Myeloid L... | Isatuximab Dexamethasone o... Fludarabine Cytarabine Liposomal dauno... Daunorubicin (n... Idarubicin Filgrastim or e... Mitoxantrone Doxorubicin Vincristine Pegaspargase (P... Cyclophosphamid... Etoposide Methotrexate L - Asparginase Hydroxyurea L - Asparaginas... | 28 Days - 17 Years | Sanofi | |
| The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer | NCT03814447 | Ovarian Cancer | anti- MESO CAR-... Fludarabine Cyclophosphamid... | 18 Years - 75 Years | Shanghai 6th People's Hospital | |
| Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) | NCT01471444 | Disorder Relate... Leukemia Transplantation... | Fludarabine Clofarabine Busulfan Thymoglobulin Stem Cell Infus... Tacrolimus Methotrexate | 3 Years - 70 Years | M.D. Anderson Cancer Center | |
| Phase II Trial in Elderly Patients With AML or MDS in Complete Remission Not Eligible for Allogenic Transplant | NCT03961919 | Acute Myeloid L... Myelodysplastic... Transplant-Rela... | Fludarabine ARA-C Treosulfan Peripheral Bloo... | 65 Years - | IRCCS San Raffaele | |
| Intravenous Autologous CD19 CAR-T Cells for R/R B-ALL | NCT03937544 | Relapsed B Acut... Refractory B Ac... | CD19 CAR-T CELL... Cyclophosphamid... Fludarabine | 13 Years - 65 Years | National University of Malaysia | |
| Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma | NCT05605899 | High-risk Large... | Axicabtagene Ci... Cyclophosphamid... Fludarabine Etoposide Rituximab Doxorubicin Vincristine Prednisone | 18 Years - | Gilead Sciences | |
| Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation | NCT04339101 | Acute Leukemia Hematologic and... Myelodysplastic... Primary Myelofi... Secondary Myelo... | Fludarabine Itacitinib Adip... Melphalan Quality-of-Life... Questionnaire A... Sirolimus Tacrolimus | 18 Years - 75 Years | City of Hope Medical Center | |
| Treg Cells for AGVHD in Non-myeloablative UCB Transplant | NCT02118311 | Hematologic Mal... | T Regulatory ce... Fludarabine Cyclophosphamid... Total Body Irra... | 18 Years - 69 Years | Masonic Cancer Center, University of Minnesota | |
| Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation | NCT04626726 | Adult B Acute L... | CD19 CAR-T CD22 CAR-T CD19+CD22 CAR-T Fludarabine Cyclophosphamid... | 14 Years - 65 Years | Hebei Senlang Biotechnology Inc., Ltd. | |
| Cellular Therapy With Cord Blood Cells | NCT00427557 | Multiple Myelom... Leukemia Lymphoma | Fludarabine Melphalan Umbilical Cord ... Rituximab Peripheral Bloo... | - 80 Years | M.D. Anderson Cancer Center | |
| Nivolumab With Chemotherapy in Refractory MDS | NCT03259516 | Myelodysplastic... | Nivolumab Azacitidine Fludarabine Cyclophosphamid... Cytarabine all trans retin... Sildenafil Melphalan | 18 Years - 80 Years | St. Petersburg State Pavlov Medical University | |
| Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer | NCT03215810 | Non-Small Cell ... Metastatic Non-... Squamous Cell C... Advanced NSCLC Adenosquamous C... Adenocarcinomas | Tumor-infiltrat... Nivolumab Cyclophosphamid... Fludarabine Tumor-infiltrat... Interleukin-2 (... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Randomized Double Cord Blood Transplant Study | NCT00067002 | Leukemia, Lymph... Leukemia, Myelo... Leukemia, Myelo... Lymphoma, Non-H... | Expanded alloge... One Unmanipulat... Rituxan Melphalan Thiotepa Fludarabine Cyclophosphamid... Mesna Total body irra... | 1 Month - 80 Years | M.D. Anderson Cancer Center | |
| CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma. | NCT03146533 | B Cell Lymphoma | Fludarabine Cyclophosphamid... CD19 CART | 18 Years - 70 Years | Shenzhen Second People's Hospital | |
| MESO-CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer | NCT03799913 | Ovarian Cancer | anti-MESO CAR-T... Fludarabine Cyclophosphamid... | 18 Years - 70 Years | Zhejiang University | |
| A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM) | NCT04196491 | Multiple Myelom... | bb2121 Fludarabine Cyclophosphamid... Lenalidomide | 18 Years - | Celgene | |
| CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma | NCT03710421 | Recurrent Plasm... Refractory Plas... | CS1-CAR T Thera... Cyclophosphamid... Fludarabine Leukapheresis | 18 Years - | City of Hope Medical Center | |
| Pan-T Booster Co-expressing MSLN CAR T Cell Therapy in Advanced/Metastatic Solid Tumors | NCT05693844 | Advanced or Met... | Pan-T booster c... Albumin-bound p... Cyclophosphamid... Fludarabine | 18 Years - 75 Years | Chinese PLA General Hospital | |
| CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome | NCT05617625 | Myelodysplastic... Graft Vs Host D... Graft-versus-ho... | Busulfan Melphalan Fludarabine CliniMACS CD34+... | 18 Years - 75 Years | Baptist Health South Florida | |
| A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering | NCT04426669 | Gastrointestina... Gastrointestina... Cancer of Gastr... Cancer, Gastroi... Gastrointestina... Colo-rectal Can... Pancreatic Canc... Gall Bladder Ca... Colon Cancer Esophageal Canc... Stomach Cancer | Cyclophosphamid... Fludarabine Tumor-Infiltrat... Aldesleukin | 18 Years - 70 Years | Intima Bioscience, Inc. | |
| Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer | NCT06121557 | Breast Neoplasm... | Surgery for har... Cyclophosphamid... Fludarabine Tumor-draining ... Interleukin-2 Camrelizumab Chemotherapeuti... | 18 Years - 70 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Allogeneic Natural Killer (NK) Cells in Patients With Advanced Metastatic Breast Cancer | NCT00376805 | Breast Cancer | Fludarabine Cyclophosphamid... Total body irra... Natural killer ... Interleukin-2 | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL) | NCT00941928 | Leukemia Pediatric Cance... | Epratuzumab Fludarabine Cyclophosphamid... Mesna Infusion of NK ... Interleukin-2 | - | M.D. Anderson Cancer Center | |
| GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Hepatocellular Carcinoma (HCC) | NCT05003895 | Hepatocellular ... Hepatocellular ... Metastatic Hepa... | Cyclophosphamid... CAR-T cell Fludarabine | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma | NCT01369875 | Metastatic Mela... Skin Cancer | Cyclophosphamid... Fludarabine Aldesleukin Tumor Infiltrat... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab | NCT00946023 | Lymphoma B-cell Lymphoma Non Hodgkin Lym... Chronic Lymphoc... | Fludarabine Cyclophosphamid... Total body irra... Tacrolimus Mycophenolate M... Rituximab Allogeneic Bone... | 1 Year - 75 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| URMC Related Haplo-identical Donor BMT | NCT02660281 | Hematological D... Immune Deficien... Solid Tumors Myelofibrosis Multiple Myelom... Lymphoma | Total Body Irra... Fludarabine Pre-Stem Cell I... Pre-Stem Cell I... Busulfan Melphalan Stem Cell Infus... Post-Stem Cell ... Post-Stem Cell ... Thiotepa | 6 Months - 75 Years | University of Rochester | |
| Stem Cell (Modified Bone Marrow) Transplantation in HIV-Infected Patients With Blood Cancer | NCT00005785 | Hematologic Neo... HIV Infection | GCSF Mobilized ... | - | National Institutes of Health Clinical Center (CC) | |
| Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment | NCT02881086 | Acute Lymphobla... Lymphoblastic L... | Rituximab Nelarabine PEG-Asparaginas... Cranial irradia... Imatinib Idarubicin Dexamethasone Cyclophosphamid... Fludarabine Vincristine Mercaptopurine VP16 Daunorubicin (D... Methotrexate Stem cell trans... Cytarabine Vindesine Adriamycin Prednisolone | 18 Years - 55 Years | Goethe University | |
| URMC Related Haplo-identical Donor BMT | NCT02660281 | Hematological D... Immune Deficien... Solid Tumors Myelofibrosis Multiple Myelom... Lymphoma | Total Body Irra... Fludarabine Pre-Stem Cell I... Pre-Stem Cell I... Busulfan Melphalan Stem Cell Infus... Post-Stem Cell ... Post-Stem Cell ... Thiotepa | 6 Months - 75 Years | University of Rochester | |
| HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy | NCT02143830 | Fanconi Anemia Severe Marrow F... Myelodysplastic... Acute Myelogeno... | Busulfan Cyclophosphamid... Fludarabine rabbit ATG G-CSF Peripheral bloo... | 3 Months - | Children's Hospital Medical Center, Cincinnati | |
| Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas | NCT05400109 | Non Hodgkin Lym... | UF-KURE19 CAR-T... Fludarabine Cyclophosphamid... | 18 Years - | Case Comprehensive Cancer Center | |
| Haplo Peripheral Blood Sct In GVHD Prevention | NCT04473911 | GVHD AML ALL MDS MPN CMML Hodgkin Lymphom... Non Hodgkin Lym... Blood Stem Cell... Graft Vs Host D... Acute Myeloid L... Acute Lymphobla... Myelodysplastic... Myeloproliferat... Chronic Myelomo... Chemosensitive ... | FLUDARABINE CYCLOPHOSPHAMID... TBI Melphalan Sirolimus Mycophenolate m... RGI-2001 CYCLOPHOSPHAMID... | 18 Years - 80 Years | Massachusetts General Hospital | |
| Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma | NCT02215967 | Myeloma, Plasma... Myeloma-Multipl... | Cyclophosphamid... Fludarabine Anti-B-cell mat... | 18 Years - 73 Years | National Institutes of Health Clinical Center (CC) | |
| CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer | NCT01218867 | Metastatic Canc... Metastatic Mela... Renal Cancer | Anti-VEGFR2 CAR... Cyclophosphamid... Aldesleukin Fludarabine | 18 Years - 70 Years | National Institutes of Health Clinical Center (CC) | |
| Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma | NCT01186458 | Lymphoma, Non-H... | Fludarabine Velcade Rituximab | 18 Years - | Hoosier Cancer Research Network | |
| Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab | NCT00946023 | Lymphoma B-cell Lymphoma Non Hodgkin Lym... Chronic Lymphoc... | Fludarabine Cyclophosphamid... Total body irra... Tacrolimus Mycophenolate M... Rituximab Allogeneic Bone... | 1 Year - 75 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
